TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

TOKYO, Sept 26, 2022 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have obtained ...

Methotrexate The effectiveness of oral vs subcutaneous methotrexate for the treatment of psoriasis in a registry is reported. More patients with psoriasis who were treated with subcutaneous ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous methotrexate is safe in clinical practice, and is continued longer and better tolerated than other ...

Antares Pharma, Inc. (NASDAQ: ATRS) today announced LEO Pharma's launch of OTREXUP to Dermatologists, the first U.S. Food and Drug Administration (FDA) approved subcutaneous (SC) methotrexate (MTX) ...

Safety and efficacy data on the investigational subcutaneous formulation of ORENCIA in adults with moderate to severe rheumatoid arthritis to be presented at the American College of Rheumatology ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...

Oral, rather than subcutaneous, methotrexate avoids weekly injections, reduces costs and might improve quality of life in children with Crohn's disease. 226 children with Crohn's disease were included ...

Methotrexate is an immunosuppressive agent which blocks DNA synthesis by inhibiting dihydrofolate reductase. It is typically given either as a single weekly dose of 7.5 to 25 mg per week or divided ...